Compare Intel Corp (INTC) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Medtronic PLC — how do they compare? Intel Corp trades at $109.22 (market cap $597.96B), while Medtronic PLC trades at $87.8 (market cap $109.38B). The key difference: Intel Corp is far larger — about 5.5× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Medtronic PLC for 63 Days on average.
| INTC | MDT | |
|---|---|---|
Market Cap | $597.96B | $109.38B |
Volume | 82,330,296 | 55,890,185 |
Sector | Technology | Health |
52-Week High | $140.94 | $105.35 |
52-Week Low | $33.62 | $73.75 |
Typical Hold Time | 116 Days | 63 Days |
Enterprise Value | $618.77B | $128.71B |
Dividend Yield | 2.24% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $107.08, down 4.82% today but maintains a bullish technical outlook with strong 2026 performance. The stock has surged over 220% year-to-date, driven by AI momentum and foundry growth. Recent earnings beats and High-NA chipmaking progress signal operational improvement, though negative profitability metrics and high valuations present challenges. Technical indicators show bullish momentum with key support at $109.
Intel's turnaround story shows promise with foundry revenue growth and government support, but faces execution risks against dominant competitors. The stock trades near analyst consensus target of $111.72, offering modest upside potential. Key risks include competitive pressures, margin challenges, and high debt levels that could limit near-term shareholder returns.
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
